<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9446">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00750360</url>
  </required_header>
  <id_info>
    <org_study_id>218352/054</org_study_id>
    <nct_id>NCT00750360</nct_id>
  </id_info>
  <brief_title>Study to Monitor the Safety and Reactogenicity of Fluarix™ in Korean Subjects Aged &gt; 6 Months of Age.</brief_title>
  <official_title>Study to Monitor the Safety and Reactogenicity of GlaxoSmithKline Biologicals' Influenza Split Vaccine FLUARIX™ Administered According to the Prescribing Information in Korean Subjects Aged &gt; 6 Months of Age at the Time of Vaccination.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <authority>South Korea: Korea Food and Drug Administration (KFDA)</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study collects data on safety and reactogenicity of the vaccine in the local
      target population (600 or more subjects) as per the requirement of Korean Food and Drugs
      Administration (KFDA).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2003</start_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Number of Participants Reporting Severe Unsolicited Adverse Events</measure>
    <time_frame>During the 21-day follow-up period (Day 0 to Day 20) after vaccination</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting Solicited Local and General Adverse Events in Subjects Aged Less Than 72 Months.</measure>
    <time_frame>During the 4-day follow up (Day 0 to 3) after vaccination.</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting Solicited Local and General Adverse Events in Subjects Aged 72 Months and Older.</measure>
    <time_frame>During the 4-day follow up (Day 0 to 3) after vaccination.</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participant Reporting Unsolicited Adverse Events.</measure>
    <time_frame>During the 21-day follow-up period (Day 0 to Day 20) after vaccination</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting Serious Adverse Events (SAE).</measure>
    <time_frame>Within 1 month following vaccination</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">883</enrollment>
  <condition>Seasonal Influenza</condition>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects aged &lt; 9 years who were previously not vaccinated against influenza</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects aged ≥ 9 years and subjects 6 months to 9 years who have previously been vaccinated against influenza</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>FluarixTM</intervention_name>
    <description>All subjects will receive a single dose of FluarixTM. For children less than 9 years of age who have not previously been vaccinated against influenza, a second dose will be given after an interval of at least 4 weeks (Group B).</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A male or female &gt; 6 months of age at the time of the first vaccination.

          -  Subjects who the investigator believes that they and/or their parents/guardians can
             and will comply with the requirements of the protocol should be enrolled in the
             study.

          -  Free of obvious health problems as established by medical history and clinical
             examination judged by the investigator before entering into the study.

          -  If the subject is female, she must be of non-childbearing potential, or, if of
             childbearing potential, she must be abstinent or have used adequate contraceptive
             precautions for 30 days prior to vaccination, have a negative pregnancy test and must
             agree to continue such precautions for two months after vaccination.

        Exclusion Criteria:

          -  Clinical signs of acute febrile illness at the time of entry into the study.

          -  Any treatment with immunosuppressive drugs, including oral and parenteral
             corticosteroids.

          -  History of allergic disease or reactions likely to be exacerbated by any component of
             the vaccine or previous severe reaction to influenza virus vaccine.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <removed_countries>
    <country>Korea, Republic of</country>
  </removed_countries>
  <verification_date>April 2009</verification_date>
  <lastchanged_date>April 8, 2009</lastchanged_date>
  <firstreceived_date>September 9, 2008</firstreceived_date>
  <firstreceived_results_date>December 23, 2008</firstreceived_results_date>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>GSK</organization>
  </responsible_party>
  <keyword>Influenza</keyword>
  <keyword>FluarixTM</keyword>
  <keyword>Korea</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Unprimed, &gt; 6 to &lt; 72 Months</title>
          <description>Subjects aged &gt; 6 months to &lt; 72 months who were previously not vaccinated against influenza (unprimed).</description>
        </group>
        <group group_id="P2">
          <title>Unprimed, ≥ 72 to &lt; 108 Months</title>
          <description>Subjects aged ≥ 72 months to &lt; 108 months who were previously not vaccinated against influenza (unprimed).</description>
        </group>
        <group group_id="P3">
          <title>Primed, &gt; 6 to &lt; 72 Months</title>
          <description>Subjects aged &gt; 6 months to &lt; 72 months who previously received a vaccination against influenza (primed).</description>
        </group>
        <group group_id="P4">
          <title>Primed, ≥ 72 to &lt; 108 Months</title>
          <description>Subjects aged ≥ 72 months to &lt; 108 months who previously received a vaccination against influenza (primed).</description>
        </group>
        <group group_id="P5">
          <title>Primed, ≥ 108 to &lt; 216 Months</title>
          <description>Subjects aged ≥ 108 months to &lt; 216 months who previously received a vaccination against influenza (primed).</description>
        </group>
        <group group_id="P6">
          <title>Primed, ≥ 216 Months</title>
          <description>Subjects aged ≥ 216 months who previously received a vaccination against influenza (primed).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="294">Seven subjects enrolled in this group were not vaccinated and as such not included as &quot;STARTED&quot;.</participants>
                <participants group_id="P2" count="1">One subject enrolled in this group was not vaccinated and as such not included as &quot;STARTED&quot;.</participants>
                <participants group_id="P3" count="384"/>
                <participants group_id="P4" count="79"/>
                <participants group_id="P5" count="46"/>
                <participants group_id="P6" count="71"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="294"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="384"/>
                <participants group_id="P4" count="79"/>
                <participants group_id="P5" count="46"/>
                <participants group_id="P6" count="71"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Unprimed, &gt; 6 to &lt; 72 Months</title>
          <description>Subjects aged &gt; 6 months to &lt; 72 months who were previously not vaccinated against influenza (unprimed).</description>
        </group>
        <group group_id="B2">
          <title>Unprimed, ≥ 72 to &lt; 108 Months</title>
          <description>Subjects aged ≥ 72 months to &lt; 108 months who were previously not vaccinated against influenza (unprimed).</description>
        </group>
        <group group_id="B3">
          <title>Primed, &gt; 6 to &lt; 72 Months</title>
          <description>Subjects aged &gt; 6 months to &lt; 72 months who previously received a vaccination against influenza (primed).</description>
        </group>
        <group group_id="B4">
          <title>Primed, ≥ 72 to &lt; 108 Months</title>
          <description>Subjects aged ≥ 72 months to &lt; 108 months who previously received a vaccination against influenza (primed).</description>
        </group>
        <group group_id="B5">
          <title>Primed, ≥ 108 to &lt; 216 Months</title>
          <description>Subjects aged ≥ 108 months to &lt; 216 months who previously received a vaccination against influenza (primed).</description>
        </group>
        <group group_id="B6">
          <title>Primed, ≥ 216 Months</title>
          <description>Subjects aged ≥ 216 months who previously received a vaccination against influenza (primed).</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="294"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="384"/>
                <measurement group_id="B4" value="79"/>
                <measurement group_id="B5" value="46"/>
                <measurement group_id="B6" value="71"/>
                <measurement group_id="B7" value="875"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="13.7" spread="10.60"/>
                <measurement group_id="B2" value="85.0" spread="0"/>
                <measurement group_id="B3" value="38.3" spread="18.80"/>
                <measurement group_id="B4" value="86.4" spread="10.60"/>
                <measurement group_id="B5" value="132.7" spread="22.00"/>
                <measurement group_id="B6" value="454.5" spread="174.40"/>
                <measurement group_id="B7" value="73.2" spread="128.07"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="142"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="178"/>
                <measurement group_id="B4" value="41"/>
                <measurement group_id="B5" value="27"/>
                <measurement group_id="B6" value="56"/>
                <measurement group_id="B7" value="445"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="152"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="206"/>
                <measurement group_id="B4" value="38"/>
                <measurement group_id="B5" value="19"/>
                <measurement group_id="B6" value="15"/>
                <measurement group_id="B7" value="430"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting Severe Unsolicited Adverse Events</title>
        <description>An Adverse Event is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
Severe unsolicited adverse events are defined as adverse events which prevent normal, everyday activities</description>
        <time_frame>During the 21-day follow-up period (Day 0 to Day 20) after vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Unprimed, &gt; 6 to &lt; 72 Months</title>
            <description>Subjects aged &gt; 6 months to &lt; 72 months who were previously not vaccinated against influenza (unprimed).</description>
          </group>
          <group group_id="O2">
            <title>Unprimed, ≥ 72 to &lt; 108 Months</title>
            <description>Subjects aged ≥ 72 months to &lt; 108 months who were previously not vaccinated against influenza (unprimed).</description>
          </group>
          <group group_id="O3">
            <title>Primed, &gt; 6 to &lt; 72 Months</title>
            <description>Subjects aged &gt; 6 months to &lt; 72 months who previously received a vaccination against influenza (primed).</description>
          </group>
          <group group_id="O4">
            <title>Primed, ≥ 72 to &lt; 108 Months</title>
            <description>Subjects aged ≥ 72 months to &lt; 108 months who previously received a vaccination against influenza (primed).</description>
          </group>
          <group group_id="O5">
            <title>Primed, ≥ 108 to &lt; 216 Months</title>
            <description>Subjects aged ≥ 108 months to &lt; 216 months who previously received a vaccination against influenza (primed).</description>
          </group>
          <group group_id="O6">
            <title>Primed, ≥ 216 Months</title>
            <description>Subjects aged ≥ 216 months who previously received a vaccination against influenza (primed).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="294"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="384"/>
                  <measurement group_id="O4" value="79"/>
                  <measurement group_id="O5" value="46"/>
                  <measurement group_id="O6" value="71"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants Reporting Severe Unsolicited Adverse Events</title>
            <description>An Adverse Event is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
Severe unsolicited adverse events are defined as adverse events which prevent normal, everyday activities</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting Solicited Local and General Adverse Events in Subjects Aged Less Than 72 Months.</title>
        <description>Solicited local adverse events assessed include induration, pain, redness, and swelling. Solicited general adverse events assessed include fever, shivering, and sweating/diaphoresis.</description>
        <time_frame>During the 4-day follow up (Day 0 to 3) after vaccination.</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Group B (Unprimed), &gt; 6 Months to &lt; 72 Months</title>
            <description>Subjects aged &gt; 6 months to &lt; 72 months who were previously not vaccinated against influenza (unprimed).</description>
          </group>
          <group group_id="O2">
            <title>Group A (Primed), &gt; 6 Months to &lt; 72 Months</title>
            <description>Subjects aged &gt; 6 months to &lt; 72 months who previously received a vaccination against influenza (primed).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="294"/>
                  <measurement group_id="O2" value="384"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants Reporting Solicited Local and General Adverse Events in Subjects Aged Less Than 72 Months.</title>
            <description>Solicited local adverse events assessed include induration, pain, redness, and swelling. Solicited general adverse events assessed include fever, shivering, and sweating/diaphoresis.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Induration</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="22"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="58"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Redness</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="40"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Swelling</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="36"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fever</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Shivering</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Sweating/diaphoresis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting Solicited Local and General Adverse Events in Subjects Aged 72 Months and Older.</title>
        <description>Solicited local adverse events assessed include induration, pain, redness, and swelling. Solicited general adverse events assessed include fatigue, fever, shivering, malaise, myalgia, headache, and sweating/diaphoresis.</description>
        <time_frame>During the 4-day follow up (Day 0 to 3) after vaccination.</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Group B (Unprimed), ≥ 72 Months to &lt; 108 Months</title>
            <description>Subjects aged ≥ 72 months to &lt; 108 months who were previously not vaccinated against influenza (unprimed).</description>
          </group>
          <group group_id="O2">
            <title>Group A (Primed), ≥ 72 Months to &lt; 108 Months</title>
            <description>Subjects aged ≥ 72 months to &lt; 108 months who previously received a vaccination against influenza (primed).</description>
          </group>
          <group group_id="O3">
            <title>Group A (Primed), ≥ 108 Months to &lt; 216 Months</title>
            <description>Subjects aged ≥ 108 months to &lt; 216 months who previously received a vaccination against influenza (primed).</description>
          </group>
          <group group_id="O4">
            <title>Group A (Primed), ≥ 216 Months</title>
            <description>Subjects aged ≥ 216 months who previously received a vaccination against influenza (primed).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="79"/>
                  <measurement group_id="O3" value="46"/>
                  <measurement group_id="O4" value="71"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants Reporting Solicited Local and General Adverse Events in Subjects Aged 72 Months and Older.</title>
            <description>Solicited local adverse events assessed include induration, pain, redness, and swelling. Solicited general adverse events assessed include fatigue, fever, shivering, malaise, myalgia, headache, and sweating/diaphoresis.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="23"/>
                  <measurement group_id="O3" value="7"/>
                  <measurement group_id="O4" value="10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Redness</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="11"/>
                  <measurement group_id="O3" value="7"/>
                  <measurement group_id="O4" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Swelling</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="10"/>
                  <measurement group_id="O3" value="6"/>
                  <measurement group_id="O4" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Induration</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="8"/>
                  <measurement group_id="O3" value="5"/>
                  <measurement group_id="O4" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fatigue</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="3"/>
                  <measurement group_id="O4" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fever</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Headache</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="4"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Malaise</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Myalgia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="6"/>
                  <measurement group_id="O3" value="3"/>
                  <measurement group_id="O4" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Shivering</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Sweating/diaphoresis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participant Reporting Unsolicited Adverse Events.</title>
        <description>An Adverse Event is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.</description>
        <time_frame>During the 21-day follow-up period (Day 0 to Day 20) after vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Unprimed, &gt; 6 to &lt; 72 Months</title>
            <description>Subjects aged &gt; 6 months to &lt; 72 months who were previously not vaccinated against influenza (unprimed).</description>
          </group>
          <group group_id="O2">
            <title>Unprimed, ≥ 72 to &lt; 108 Months</title>
            <description>Subjects aged ≥ 72 months to &lt; 108 months who were previously not vaccinated against influenza (unprimed).</description>
          </group>
          <group group_id="O3">
            <title>Primed, &gt; 6 to &lt; 72 Months</title>
            <description>Subjects aged &gt; 6 months to &lt; 72 months who previously received a vaccination against influenza (primed).</description>
          </group>
          <group group_id="O4">
            <title>Primed, ≥ 72 to &lt; 108 Months</title>
            <description>Subjects aged ≥ 72 months to &lt; 108 months who previously received a vaccination against influenza (primed).</description>
          </group>
          <group group_id="O5">
            <title>Primed, ≥ 108 to &lt; 216 Months</title>
            <description>Subjects aged ≥ 108 months to &lt; 216 months who previously received a vaccination against influenza (primed).</description>
          </group>
          <group group_id="O6">
            <title>Primed, ≥ 216 Months</title>
            <description>Subjects aged ≥ 216 months who previously received a vaccination against influenza (primed).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="294"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="384"/>
                  <measurement group_id="O4" value="79"/>
                  <measurement group_id="O5" value="46"/>
                  <measurement group_id="O6" value="71"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participant Reporting Unsolicited Adverse Events.</title>
            <description>An Adverse Event is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="28"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="67"/>
                  <measurement group_id="O4" value="12"/>
                  <measurement group_id="O5" value="6"/>
                  <measurement group_id="O6" value="3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting Serious Adverse Events (SAE).</title>
        <description>An SAE is any untoward medical occurrence that:
results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.</description>
        <time_frame>Within 1 month following vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Unprimed, &gt; 6 to &lt; 72 Months</title>
            <description>Subjects aged &gt; 6 months to &lt; 72 months who were previously not vaccinated against influenza (unprimed).</description>
          </group>
          <group group_id="O2">
            <title>Unprimed, ≥ 72 to &lt; 108 Months</title>
            <description>Subjects aged ≥ 72 months to &lt; 108 months who were previously not vaccinated against influenza (unprimed).</description>
          </group>
          <group group_id="O3">
            <title>Primed, &gt; 6 to &lt; 72 Months</title>
            <description>Subjects aged &gt; 6 months to &lt; 72 months who previously received a vaccination against influenza (primed).</description>
          </group>
          <group group_id="O4">
            <title>Primed, ≥ 72 to &lt; 108 Months</title>
            <description>Subjects aged ≥ 72 months to &lt; 108 months who previously received a vaccination against influenza (primed).</description>
          </group>
          <group group_id="O5">
            <title>Primed, ≥ 108 to &lt; 216 Months</title>
            <description>Subjects aged ≥ 108 months to &lt; 216 months who previously received a vaccination against influenza (primed).</description>
          </group>
          <group group_id="O6">
            <title>Primed, ≥ 216 Months</title>
            <description>Subjects aged ≥ 216 months who previously received a vaccination against influenza (primed).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="294"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="384"/>
                  <measurement group_id="O4" value="79"/>
                  <measurement group_id="O5" value="46"/>
                  <measurement group_id="O6" value="71"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants Reporting Serious Adverse Events (SAE).</title>
            <description>An SAE is any untoward medical occurrence that:
results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Unprimed, &gt; 6 to &lt; 72 Months</title>
          <description>Subjects aged &gt; 6 months to &lt; 72 months who were previously not vaccinated against influenza (unprimed).</description>
        </group>
        <group group_id="E2">
          <title>Unprimed, ≥ 72 to &lt; 108 Months</title>
          <description>Subjects aged ≥ 72 months to &lt; 108 months who were previously not vaccinated against influenza (unprimed).</description>
        </group>
        <group group_id="E3">
          <title>Primed, &gt; 6 to &lt; 72 Months</title>
          <description>Subjects aged &gt; 6 months to &lt; 72 months who previously received a vaccination against influenza (primed).</description>
        </group>
        <group group_id="E4">
          <title>Primed, ≥ 72 to &lt; 108 Months</title>
          <description>Subjects aged ≥ 72 months to &lt; 108 months who previously received a vaccination against influenza (primed).</description>
        </group>
        <group group_id="E5">
          <title>Primed, ≥ 108 to &lt; 216 Months</title>
          <description>Subjects aged ≥ 108 months to &lt; 216 months who previously received a vaccination against influenza (primed).</description>
        </group>
        <group group_id="E6">
          <title>Primed, ≥ 216 Months</title>
          <description>Subjects aged ≥ 216 months who previously received a vaccination against influenza (primed).</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1"/>
                <counts group_id="E2" subjects_affected="0"/>
                <counts group_id="E3" subjects_affected="0"/>
                <counts group_id="E4" subjects_affected="0"/>
                <counts group_id="E5" subjects_affected="0"/>
                <counts group_id="E6" subjects_affected="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Kawasaki’s disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="384"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5.0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7"/>
                <counts group_id="E2" subjects_affected="0"/>
                <counts group_id="E3" subjects_affected="58"/>
                <counts group_id="E4" subjects_affected="23"/>
                <counts group_id="E5" subjects_affected="7"/>
                <counts group_id="E6" subjects_affected="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="58" subjects_at_risk="384"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="46"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Redness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="384"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="46"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="384"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="46"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Induration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="384"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="46"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>
